AEON Biopharma, Inc. (AEON)

AEON Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022
Selling, General & Admin	12.21	13.64	19.79	19.79	-
Research & Development	4.09	14.18	381.05	381.05	-
Other Operating Expenses	-3.5	-100.81	-52.75	-52.75	3.33
Total Operating Expenses	12.8	-72.99	348.09	348.09	3.33
Operating Income	-12.8	72.99	-334.16	-334.16	-3.33
Interest Income	-	-	-	-	3.71
Other Non-Operating Income (Expense)	-0.24	-30.98	-36.69	-36.69	6.88
Total Non-Operating Income (Expense)	-0.24	-30.98	-36.69	-36.69	10.58
Pretax Income	-39.22	42.01	-384.63	-384.63	7.26
Provision for Income Taxes	-	-	-	-	0.88
Net Income	-39.22	42.01	-384.63	-384.63	6.38
Net Income to Common	-39.22	42.01	-384.63	-384.63	6.38
Net Income Growth	-	-	-	-	-22.26%
Shares Outstanding (Basic)	10	1	1	1	2
Shares Outstanding (Diluted)	10	1	1	1	2
Shares Change (YoY)	1622.66%	11.59%	-	-73.24%	-99.89%
EPS (Basic)	-3.95	77.74	46.80	46.80	-27.36
EPS (Diluted)	-3.95	72.93	46.80	46.80	-27.36
EPS Growth	-	55.83%	0%	-	-
Shares Outstanding	12.11	0.56	0.52	0.12	0.48
Free Cash Flow	-17.31	-20.29	0	0	-0.98
Free Cash Flow Per Share	-1.74	-35.23	-	-	-0.51
EBITDA	-12.73	73.08	-334.16	-334.16	-3.33
EBIT	-12.8	72.99	-334.16	-334.16	-3.33
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	12.17%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q